康莱特联合顺铂治疗恶性胸腔积液的临床疗效

Clinical efficacy of Kanglaite injection combined with cis-platinum for malignant pleural effusion

目的探讨康莱特联合顺铂治疗恶性胸腔积液的临床疗效。方法回顾性分析恶性胸腔积液患者36例的临床资料。16例患者采用康莱特联合顺铂胸腔注入治疗为研究组,20例患者采用顺铂胸腔注入治疗为对照组。比较两组患者治疗24 h和48 h后胸腔积液PAI-1、TGF-β、TNF-α水平变化,比较两组患者治疗4周后的临床疗效、不良反应。结果治疗48 h,研究组胸腔积液PAI-1、TGF-β、TNF-α水平显著高于对照组(P<0.01);治疗4周后,研究组胸水乳酸脱氢酶水平(721.9±80.3 U/L)显著高于对照组,癌胚抗原水平(7.9±2.1μg/L)显著低于对照组(P<0.01),研究组完全缓解率(50.00%)显著高于对照组(P<0.01)。结论康莱特联合顺铂治疗恶性胸腔积液具有较好的临床疗效,有利于胸膜纤维化,并且能够提高完全缓解率,减轻不良反应。

Objective To discuss clinical efficacy of Kanglaite Injection combined with cis-platinum for malignant pleural effusion. Methods Clinical data of 36 cases with malignant pleural effusion were retrospectively analyzed. 16 cases of study group were treated by Kanglaite injection combined with cis-platinum intrathoracic injection, and 20 cases of control group were treated by cis-platinum intrathoracic injection. Changes of pleural effusion PAI-1、TGF-β、TNF-αlevels at 24 h and 48 h after treatment of two groups were compared. Clinical efficacy and adverse reactions af-ter 4 weeks of two group were compared. Results Treatment of 48 h, pleural effusion PAI-1、TGF-β、TNF-αlevels of study group were higher than control group（P〈0.01）. Pleural effusion 4 weeks, pleural effusion LDH level（721.9±80.3 U/L） of study group was higher than control group, CEA（7.9±2.1μg/L） was lower than control group, and CR （50.00%） was higher than control group（10.00%）（P〈0.01）. Conclusion Kanglaite injection combined with cis-platinum for ma-lignant pleural effusion shows good clinical efficacy, is advantageous to the pleural fibrosis, and can improve CR and reduce adverse reactions.